네오이뮨텍

950220KOSDAQ

60.2 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment18.7 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 64.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Neoimmune Tech is a biotech company specializing in T cell-based immunotherapy, with NT-I7, a long-acting T cell booster, as its core pipeline. The company is developing treatments for Acute Radiation Syndrome (ARS) and CAR-T combination therapies, while also holding an exclusive North American license for Endari®, an FDA-approved sickle cell disease treatment, to drive commercialization.

Number of Employees

40people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-64.24Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

3.63Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.6% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -62.4% (declining, 3yr)

Detailed News Sentiment

17 totalPositive 11Neutral 5Negative 1Average Sentiment Score 74.7

Neutral
코스닥 기술특례상장 300곳 넘었다…제도 도입 21년 만
코스닥 기술특례상장 기업 수가 300곳을 돌파했으나, 직접적인 영향은 제한적임.
Neutral
코스닥 ‘기술특례상장’ 21년 만에 300호 기업 배출… 신규 상장 ...
기술특례상장 제도를 통해 스카이랩스가 코스닥에 상장되었으나, 직접적인 영향은 네오이뮨텍의 주가에 미치지 않는다.
Neutral
기술특례상장 제도 도입 21년 만에 상장사 300개 달성
기술특례상장 제도의 성공적인 성과로 전체 상장 기업 수가 증가했으나, 네오이뮨텍에 직접적인 영향은 미미함.

Detailed Momentum

52-week position6.0Point

52w upper range (79%)

Current 2,510Won52-week high 3,05052-week low 384

1-month return6.0Point

1m +64.16% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-09-04
Neutral기업설명회(IR)개최2026-08-19
Neutral투자판단관련주요경영사항 (NTI7 흉선 기능 관련 적응증에 대한 독점적 기술이전 계약 체결)2026-08-19
Neutral투자판단관련주요경영사항(임상시험결과) (NIT110(재발성·불응성 진행성 고형암, NTI7 및 키트루다 병용요법) 임상 1b/2a상 임상시험결과보고서(CSR) 수령)2026-08-18
Neutral반기보고서 (2026.06)2026-08-12